Agios Pharmaceuticals is executing a commercial inflection with PYRUKYND, as evidenced by a 116% sequential revenue surge to $44.7M in 2026Q2 and gross margin expansion to 93.3%. However, the company remains deeply unprofitable, with operating losses of -$110....
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | -$1.69-2.4% vs -$1.65 | $45M+69.5% vs $26M |
Q2 2026 Apr 29, 2026 | -$1.69+6.6% vs -$1.81 | $21M+56.0% vs $13M |
Q1 2026 Feb 12, 2026 | -$1.85+6.1% vs -$1.97 | $20M+65.1% vs $12M |
Q4 2025 Oct 30, 2025 | -$1.78+7.8% vs -$1.93 | $13M+10.1% vs $12M |
Bank of New York Mellon Corp purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 198,685 shares of the biopharmaceutical company's stock, valued at approximately $7,373,000. Bank of
Agios is leveraging mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease to build a durable rare-disease franchise. Thalassemia launch drove Q2 2026 mitapivat revenue to $44.7M, up 259% YoY, with strong payer coverage and operational leverage emerging. AGIO's $965M cash position supports pipeline expansion and mitigates near-term dilution risk ahead of the November 1, 2026, PDUFA for mitapivat in sickle cell.
Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 54.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 103,955 shares of the biopharmaceutical company's stock after acquiring an additional 36,802 shares during the quarter. Assenagon
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) has been assigned a consensus rating of "Hold" from the ten research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have issued a buy recommendation on the
Benchmark AGIO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Agios Pharmaceuticals, Inc. (AGIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.19 | $2.03B | -4.80 | 48.03% | -764.01% | -30.2% | — | |
| $43.93 | $7.3B | -18.46 | 33.87% | -64.64% | -110.84% | — | |
| $62.34 | $5.17B | 8.01 | 114.51% | -3.8% | — | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — |
Agios Pharmaceuticals, Inc. (AGIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Agios Pharmaceuticals, Inc. (AGIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 18, 2026·SEC
Apr 29, 2026·SEC
Get notified when AGIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Agios Pharmaceuticals, Inc. (AGIO) stock FAQ — growth, dividends, profitability & financials explained
Agios Pharmaceuticals, Inc. (AGIO) reported $98.3M in revenue for fiscal year 2025. This represents a 350% increase from $21.8M in 2011.
Agios Pharmaceuticals, Inc. (AGIO) grew revenue by 48.0% over the past year. This is strong growth.
Agios Pharmaceuticals, Inc. (AGIO) reported a net loss of $411.3M for fiscal year 2025.
Agios Pharmaceuticals, Inc. (AGIO) has a return on equity (ROE) of -30.2%. Negative ROE indicates the company is unprofitable.
Agios Pharmaceuticals, Inc. (AGIO) had negative free cash flow of $365.3M in fiscal year 2025, likely due to heavy capital investments.
